Vardenafil hydrochloride is supplied as a pharma grade API for tablet, capsule, granule, oral, and injectable dosage forms. The substance is the monohydrochloride trihydrate salt of a phosphodiesterase type 5 inhibitor, with empirical formula C₂₃H₃₂N₆O₄S·HCl·3H₂O, molecular weight 579.1 g/mol, and CAS Registry Number 224785-90-4. The crystalline powder is white to off-white, and the trihydrate stoichiometry corresponds to a theoretical water content of 9.3% w/w; this lattice water must be preserved during processing unless an anhydrous or amorphous form is deliberately generated. The API is designated by its trihydrate lattice and route-specific particle-size grade rather than a separate model number; the oral grade is controlled for solid-dosage performance, and the injectable grade is controlled for endotoxin and particulate burden. The finished oral products are low-dose forms with unit doses from 2.5 mg to 20 mg, where content uniformity and blend segregation dominate process design. For oral administration, vardenafil undergoes extensive CYP3A4-mediated first-pass metabolism, and published absolute bioavailability is approximately 15%; this property distinguishes vardenafil from tadalafil and influences the milled particle-size distribution needed for consistent dissolution.

Direct-compression tablet manufacture at 1.0% w/w or lower drug load demands geometric dilution steps and a final blend relative standard deviation not more than 3.0%. In production-scale trials using a 500 L bin blender, vardenafil HCl trihydrate with D90 below 20 µm exhibited electrostatic adhesion to stainless steel surfaces; this is managed by pre-mixing with microcrystalline cellulose and using 0.5–1.0% w/w magnesium stearate as a lubricant. For high-shear wet granulation, an impeller tip speed of 4–7 m/s and a granulation end-point torque of 8–12 N·m produce agglomerates with a D50 of 150–250 µm, suitable for capsule filling and tablet compression. These values are representative of pilot-scale equipment and may shift with bowl geometry.

Crystalline hydrate stoichiometry and release specification interface

The release profile for oral and injectable grades is anchored to the trihydrate crystal form. X-ray powder diffraction must match the manufacturer-established reference pattern, with characteristic peaks reproduced within ±0.2° 2θ. Because the trihydrate releases lattice water in low-dew-point drying systems, vacuum drying for solvent removal should be conducted below 50°C and at not less than 10% relative humidity to avoid partial dehydration and form conversion. The acceptance criteria below are representative of a commercial release specification and are aligned to United States Pharmacopeia and European Pharmacopoeia methodology.

The water content window of 9.0%–10.5% is not a general moisture specification; it specifically reflects the trihydrate lattice and prevents anhydrous or lower-hydrate contamination. If the API is intended for anhydrous solvent wet granulation followed by drying, the drying curve must be monitored by loss on drying at 105°C and by XRPD, not by Karl Fischer alone, to distinguish lattice water from process water. Residual solvent controls follow ICH Q3C, but if injectable-grade powder is requested, the residual solvent panel is expanded to include Class 2 solvents and the material is packed in glass vials with nitrogen overlay to reduce oxygen and moisture ingress. Because the molecule contains a piperazine-derived structural alert, a nitrosamine impurity risk assessment according to ICH M7 is conducted at the batch level. The control strategy employs a mass spectrometric target limit derived from the acceptable intake of the relevant nitrosamine and the maximum daily dose of vardenafil; no generic ppm limit is assigned without specification of the dose.

Does the hydrochloride trihydrate impose a different impurity-control strategy than the citrate or free-base forms?

In pre-formulation screening, vardenafil hydrochloride differs from sildenafil citrate and tadalafil in salt form, molar mass, aqueous solubility, and elimination half-life. These differences alter wet granulation solvent selection, dissolution-rate control, and the need for pH modifiers. The comparative values below are drawn from published pharmacologically relevant data and pharmacopoeial chemical descriptions; they are not release specifications.

Sildenafil citrate is a citrate salt with molecular weight 666.7 g/mol and is usually formulated at higher unit doses, while tadalafil is a free base with molecular weight 389.4 g/mol and a much longer elimination half-life of 17.5 h. Vardenafil hydrochloride trihydrate has a reported in vitro PDE5 IC50 in the 0.1–1 nM range; this is lower than the commonly reported sildenafil range of 3–5 nM, but in vitro potency alone does not determine the clinical dose due to absorption, protein binding, and first-pass metabolism. The hydrochloride salt can exhibit greater hygroscopic response in high-humidity open handling than the free base tadalafil, so container closure and desiccant control are more stringent for vardenafil. For oral immediate-release tablets, the use of a pH-adjusting or acidifying excipient is often required to overcome the pH-dependent solubility decline above the pKa.

When capsule and granule intermediates require fluid-bed processing, the controlling parameter becomes agglomerate porosity

For capsule and granule filling, granule porosity controls disintegration and drug release. Granules with porosity below 10% from high-density roller compaction may resist wicking and produce slow dissolution, while porosity above 25% can cause attrition and capsule weight variability. A fluid-bed granulator set to an inlet air temperature of 60–70°C and spray rate of 10–20 g/min/kg of granulate produces granules with a porosity of 15–20% and a tapped density of 0.55–0.65 g/mL. Filling into size 3 hard gelatin capsules at a target weight of 150 mg requires granule D50 between 150 µm and 250 µm and a maximum moisture content of 1.0% as determined by loss on drying at 80°C. The granulation process should not be substituted for a single-step direct fill because the low-dose drug may segregate in a free-flowing powder blend.

Aqueous processing above pH 6.0 is avoided because the unionized free base precipitates and may generate a difficult-to-wet surface film; the hydrochloride salt is handled in acidic media below pH 4.5 for clear solution work. Strong oxidizing agents should be avoided in cleaning validation because sulfonamide and piperazine moieties can be oxidized to non-pharmacopoeial degradants.

Immediate-release vardenafil tablets are evaluated for dissolution using USP <711> apparatus 2 at 50 rpm in 0.1 N hydrochloric acid. A typical specification is not less than 80% dissolved in 30 min for a 10 mg strength. The low aqueous solubility at neutral pH means the dissolution test must not be conducted in phosphate buffer without surfactant; if surfactant is used, sodium dodecyl sulfate at 0.1–0.5% w/v must be validated against a reference batch to avoid over-discrimination. Tablet hardness values from 60–100 N are adequate to maintain friability below 1.0% without delaying disintegration beyond 15 min in water.

Injectable-grade vardenafil hydrochloride for extemporaneous or pilot parenteral preparation requires particle and microbial controls beyond solid oral grade. The API solution is typically prepared under aseptic conditions using water for injection at 25°C and pH adjusted below 4.5; terminal steam sterilization is not automatically applicable because the molecule may undergo acid-catalyzed degradation at high temperature. Sterile filtration through a 0.22 µm membrane is applied to reduce bioburden, and bacterial endotoxin is controlled to not more than 0.5 EU/mg by the Limulus amebocyte lysate test. For injectable compositions, osmolarity is adjusted to 280–320 mOsm/kg and the filled solution is checked for subvisible particles under USP <787>; published data for this specific configuration is limited.

The bulk API is packaged in double low-density polyethylene bags inside a sealed aluminium laminate overwrap. Desiccant silica gel is added when ambient relative humidity exceeds 60%, and the container is stored at 15–25°C. Light protection is critical because PDE5 inhibitors with aryl sulfonamide moieties may undergo photolytic discoloration; the material should not be exposed to direct sunlight for more than 8 h during dispensing. In-process moisture checks for a tablet compression suite located at 45% RH or below are performed every 2 h to prevent hydrate redistribution at the particle surface.